

# *Mycobacterium mucogenicum* related to granulomatosis with polyangiitis: infection or colonization?

*Mycobacterium mucogenicum*: infecção ou colonização relacionada à poliangiite granulomatosa?



Mariana Lanna Magalhães<sup>1\*</sup>

José Angelo Lauletta Lindoso<sup>1,2</sup>

<sup>1</sup> Instituto de Infectologia Emilio Ribas - São Paulo - SP - Brazil

<sup>2</sup> Faculdade de Medicina da Universidade de São Paulo, Instituto de Medicina Tropical - São Paulo - SP - Brazil



Submitted: 28 November 2023

Accepted: 19 December 2023

Published: 27 February 2024

## \*Corresponding Author:

Mariana Lanna Magalhães

E-mail: marianalanna@outlook.com

## ABSTRACT

Advances in diagnostic methods, especially molecular biology, have made the identification of microorganisms easier and more sensitive. However, this progress also requires a better assessment of the clinical significance of the isolated microorganism, since in many situations this agent may only be contaminant or tissue colonization. Non-tuberculous mycobacteria are good examples of this duality and can cause both a range of clinical infections or only colonize certain sites in the body. In this report, we describe the case of a previously healthy patient with ulcerated lesions of the skin and mucous membranes with a chronic and progressive evolution. After various tests and evaluations, granulomatosis with polyangiitis was diagnosed. However, the biopsy of the nasolabial lesion also identified the presence of *Mycobacterium mucogenicum* using molecular biology. This identification raised many doubts in the medical teams about the real role of this Non-tuberculous mycobacteria in the pathogenesis or aggravation of the lesions, with decision-making implications about its specific treatment (or not), since the patient would be undergoing immunosuppressive therapy.

**Headings:** Non-tuberculous mycobacteria; Granulomatosis with polyangiitis; Vasculitis; Molecular Biology; Case Report.

## RESUMO

O avanço dos métodos diagnósticos, principalmente da biologia molecular, tornou a identificação dos microrganismos mais fácil e sensível. No entanto, esse avanço também exige uma melhor avaliação sobre o significado clínico do microrganismo isolado, uma vez que, em muitas situações, esse agente pode ser apenas um contaminante ou uma colonização. As micobactérias não tuberculosas (MNT) são bons exemplos desta dualidade e podem tanto causar uma gama de infecções clínicas quanto apenas colonizar determinados sítios do organismo. Neste relato, descrevemos o caso de um paciente previamente hígido com lesões ulceradas de pele e mucosas de evolução crônica e progressiva. Após diversos exames e avaliações, chegou-se ao diagnóstico de granulomatose com poliangiite. Todavia a biópsia da lesão nasolabial também identificou, por meio de biologia molecular, a presença de *Mycobacterium mucogenicum*. Essa identificação suscitou muitas dúvidas nas equipes médicas sobre o real papel desta MNT na patogênese ou no agravamento das lesões, com implicações decisórias sobre o seu tratamento (ou não) específico, uma vez que o paciente seria submetido a terapia imunossupressora.

**Descritores:** Micobactérias não tuberculosas; Granulomatose com poliangiite; Vasculite; Biologia molecular; Relato de caso.

## INTRODUCTION

The *Mycobacterium mucogenicum* group includes *M. mucogenicum*, *M. aubagnense*, and *M. phocaicum*, all considered to be fast-growing mycobacteria. This group of microorganisms was initially named

DOI: 10.5935/2764-734X.e20231233-en

*Mycobacterium chelonae*-like in 1982, when it was reported as the etiologic agent of an outbreak of peritonitis involving two peritoneal dialysis units<sup>1</sup>.

Infection with *M. mucogenicum* is rare. When identified, most of the time it is colonizing a tissue or is a finding of no clinical relevance<sup>2</sup>. Individuals undergoing hemodialysis, however, as well as those who have recently undergone surgical procedures and hospitalizations, seem to be at greater risk of being colonized (or infected) by this mycobacterium, since this microorganism is present in hospital water systems<sup>3,4</sup>. *M. mucogenicum* has an important capacity for biofilm formation, which allows it to tolerate extreme temperatures and various types of disinfection<sup>5</sup>.

When the presence of *M. mucogenicum* represents active infection, it can be associated with a broad spectrum of clinical manifestations. There are reports in the literature of respiratory conditions and involvement of the skin and soft tissues, without much epidemiological relevance<sup>6</sup>. Catheter-related bloodstream infections, on the other hand, are the most common - especially long-term catheters<sup>7</sup> in immunosuppressed patients (cancer patients and bone marrow transplant patients)<sup>8</sup>. It is believed that contamination can occur during bathing, when catheters are exposed to water from the shower<sup>9</sup>.

In this case report, the presence of *Mycobacterium mucogenicum* was identified using molecular biology in a biopsy of an ulcerated lesion in the nasolabial region of a patient with granulomatosis with polyangiitis (GPA), an autoimmune disease. A discussion begun about the role of the mycobacterium in this context, as well as whether we should consider treating it, given that the patient would still be undergoing immunosuppressive therapy.

## CASE REPORT

A 30-year-old man was admitted to a tertiary referral hospital for an investigation of a chronic lesion causing significant nose deformity, with perforation of the septum and collapse of the nasal dorsum. There were also some systemic symptoms, such as weight loss (around 10 kg in the last year), asthenia and fatigue. The patient was previously healthy, with no relevant pathological or epidemiological history, born in the Chapada Diamantina region of Bahia, Brazil, but had lived in São Paulo, Brazil, since he was 14 years old. In his anamnesis, he reported frequent episodes of epistaxis and sinusitis for more than 10 years, always treated with oral antibiotics, but without complete resolution of the condition. About two years ago, he noticed the appearance of small ulcerated and crusted lesions in the nasolabial region, which, at the beginning

of the condition, disappeared spontaneously. In the last six months, these lesions have grown and agglutinated into a single larger lesion, also affecting the nasal mucosa (Figure 1A). He also mentioned that he had already received medical care at various hospitals and clinics and had even undergone biopsies and procedures such as nasofibroscope - all of which were inconclusive, ratified by reports provided by the patient himself.



**Figure 1A.** Ulcerated lesion (pre-treatment) in the nasolabial region, when the patient was admitted to hospital to begin investigation.



**Figure 1B.** Regression of the lesion after specific treatment (after one year).

The main diagnostic hypothesis at the beginning of the hospitalization was mucocutaneous leishmaniasis, but the serology was negative, as was the serology of paracoccidioidomycosis (by immunoblot). Other serological tests were also negative: anti-hepatitis C, anti-hepatitis B, VDRL and anti-HIV. Other laboratory tests showed high platelet count (758 thousand/mm<sup>3</sup>), anemia (hemoglobinemia of 8.4 g/dL) and increased C-reactive protein (CRP) (35.1 mg/L compared to the reference value of up to 10 mg/L). Computed tomography scans of the sinuses showed points of mucous thickening distributed throughout the paranasal cavities bilaterally, with protein

content in the left maxillary sinus. Part of the hard palate, the nasal septum, the middle and lower nasal turbinate and the uncinate processes were not characterized (Figure 2).



**Figure 2.** CT scan of the sinuses showing mucous thickening distributed throughout the paranasal cavities bilaterally, with protein content in the left maxillary sinus. Part of the hard palate, the nasal septum, the middle and lower nasal turbinate and the uncinate processes were not characterized.

A new biopsy of the nasolabial lesion was carried out, which histological analysis (hematoxylin and eosin, Zielh-Neelsen, Grocott and PAS staining) revealed a “chronic ulcer with acute suppurative component and atypical cellular infiltrate in the skin integument”. Histochemical tests were negative for acid-fast bacteria (AFB) and fungi. All cultures for bacteria, fungi and mycobacteria from the blood and the biopsied fragment were negative. The investigation of leishmania was again negative, this time by polymerase chain reaction (PCR). The only agent detected, also by molecular biology (PCR), was *Mycobacterium* spp, whose sequencing showed 100% nucleotide similarity with *M. mucogenicum*.

In view of the controversy surrounding the role of this mycobacterium as the causative agent of such tissue destruction, we decided to involve the rheumatology team in the multidisciplinary discussion. These experts requested several autoimmunity markers, whereas c-ANCA was reactive (with a titration of 1/60), as was anti-proteinase 3 (anti-PR3). These results led to the diagnosis of granulomatosis with polyangiitis (GPA), whose proposed treatment was pulse therapy (methylprednisolone 1000 mg daily for three days) combined with methotrexate 15 mg/week. Even in view of the immunosuppression which the patient would be subjected, the teams involved opted to not treat the mycobacterium: in addition to the c-ANCA

and anti-PR3 markers being highly specific for the diagnosis of GPA, the patient's clinical condition (epistaxis and recurrent sinusitis preceding the appearance of the nasolabial lesion) could already be explained by the underlying disease alone, with no evidence of an associated infection. *M. mucogenicum*, therefore was colonizing a chronic wound that already had an ulcerated surface for months, and previous procedures and manipulations in a hospital environment may have been a risk factor in facilitating local colonization by this microorganism.

One year after diagnosis and the start of treatment, the patient is in good condition. There was total regression and healing of the ulcerated lesions, as well as improvement in the systemic condition, with weight gain and reduced fatigue. There were no clinical manifestations suggestive of invasive or active mycobacteriosis, nor was there any worsening or the appearance of new wounds after the introduction of immunosuppressive treatment (Figure 1B).

## DISCUSSION

According to the growth time of their colonies on culture media, non-tuberculous mycobacteria (NTMs) are divided into two groups: the fast-growing ones, which produce mature colonies on agar plates within seven days; and the slow-growing mycobacteria, which take longer than seven days to grow. The *M. mucogenicum* identified in the case reported belongs to the first group<sup>10</sup>.

The ecological niche of *M. mucogenicum* is poorly known, but this species seems to be ubiquitous and mainly colonizes water systems of communities and hospitals<sup>5,9</sup>. This is why most infections caused by this pathogen are related to recent hospitalization or association with a contaminated water source.

Infections caused by NTMs have been increasingly reported in recent years, possibly due to the increase in medical conditions and treatments that compromise the immune system, such as the use of immunobiologicals, chemotherapy and transplants<sup>11</sup>, but also due to the improvement and greater availability of the techniques needed to identify it. The current gold standard for identifying mycobacteria is DNA sequencing with the 16sRNA, rpoB and hsp65 genes being recognized as useful targets, but these are not easily accessible methods in many laboratories. Mass spectrometry (MALDI-TOF) can also accurately identify species of mycobacteria<sup>12</sup>.

Despite the greater possibility that it is just contamination, the identification of NTMs in the bloodstream or in some other location that is related



to the patient's symptoms should be considered a situation that requires treatment, especially in immunocompromised individuals. It is therefore important to remember that if a NTM is identified and there is some clinical relevance, antimicrobial susceptibility testing should be arranged. In our case, there was no growth of *M. mucogenicum* in culture that would allow us to obtain this information.

Isolates of NTMs are usually susceptible to aminoglycosides, fluoroquinolones, tetracyclines, macrolides, carbapenems, cefoxitin, sulfamethoxazole-trimethoprim and linezolid. The ideal antibiotic therapy is not standardized, and many treatment regimens have been proposed. According to the consensus of the Infectious Diseases Society of America, an aminoglycoside combined with a macrolide and/or a quinolone is the most appropriate empirical treatment. The ideal duration of treatment is unknown, but at least four weeks of treatment is recommended, which can be extended between 12 and 18 months<sup>13</sup>.

In this case, it was concluded that the isolated NTM did not participate in the pathogenesis of the disease. In addition to the fact that it did not grow in culture, we did not find any reports in the literature where *M. mucogenicum* had caused this type of severe, deforming lesion, and the underlying disease - GPA - was already capable of justifying the entire clinical picture presented by the patient<sup>14</sup>. In addition, there was no recommendation for preemptive treatment for this pathogen or any other NTM, despite the immunosuppression to which the patient would be subjected to treat the GPA. The decision of the multidisciplinary team was therefore to maintain an expectant attitude, with the necessary supervision and monitoring to immediately identify any clinical and harmful manifestations that might be related to the mycobacterium.

## CONCLUSION

The presence of *M. mucogenicum* in human tissues raises doubts about its pathogenicity and clinical relevance, which makes decision-making difficult when this pathogen is identified, especially in immunosuppressed patients. In the case reported, this fast-growing mycobacterium was considered to be colonizing the tissue and was not related to the development of the lesion, since the patient had a diagnosis that explained by itself the evolution and all the signs and symptoms presented. The decision to not treat this mycobacterium proved to be the right one, because even in the face of immunosuppressive treatment for the underlying disease, there was no clinical worsening or any evidence of NTM-related activity.

*"This case report deserved an official declaration of acknowledgement and ethical approval by its institution of origin and was peer-reviewed before publication, whilst the authors declare no fundings nor any conflicts of interest concerning this paper. It is noteworthy that case reports provide a valuable learning resource for the scientific community but should not be used in isolation to guide diagnostic or treatment choices in practical care or health policies. This Open Access article is distributed under the terms of the Creative Commons Attribution License (CC-BY), which allows immediate and free access to the work and permits users to read, download, copy, distribute, print, search, link and crawl it for indexing, or use it for any other lawful purpose without asking prior permission from the publisher or the author, provided the original work and authorship are properly cited."*

## REFERENCES

1. Band JD, Ward JL, Fraser DW, Peterson NJ, Silcox VA, Good RC et al. Peritonitis due to a mycobacterium chelonae-like organism associated with intermittent chronic peritoneal dialysis. *J Infect Dis*. 1982; 145(1):9-17. DOI: 10.1093/infdis/145.1.9
2. Esteban J, Martín-de-Hijas NZ, Fernandez AI, Fernandez-Roblas R, Gadea I; Madrid Study Group of Mycobacteria. Epidemiology of infections due to nonpigmented rapidly growing mycobacteria diagnosed in an urban area. *Eur J Clin Microbiol Infect Dis*. 2008; 27(10):951-7. DOI: 10.1007/s10096-008-0521-7
3. Livni G, Yaniv I, Samra Z, Kaufman L, Solter E, Ashkenazi S et al. Outbreak of *Mycobacterium mucogenicum* bacteraemia due to contaminated water supply in a paediatric haematology-oncology department. *J Hosp Infect*. 2008; 70(3):253-8. DOI: 10.1016/j.jhin.2008.07.016
4. Adékambi T. *Mycobacterium mucogenicum* group infections: a review. *Clin Microbiol Infect*. 2009; 15(10):911-8. DOI: 10.1111/j.1469-0691.2009.03028.x
5. Simões LC, Simões M, Vieira MJ. Biofilm interactions between distinct bacterial genera isolated from drinking water. *Appl Environ Microbiol*. 2007; 73(19):6192-200. DOI: 10.1128/AEM.00837-07
6. Han XY, Dé I, Jacobson KL. Rapidly growing mycobacteria: clinical and microbiologic studies of 115 cases. *Am J Clin Pathol*. 2007; 128(4):612-21. DOI: 10.1309/1KB2GKYT1BUEYLB5
7. Hawkins C, Qi C, Warren J, Stosor V. Catheter-related bloodstream infections caused by rapidly growing non-tuberculous mycobacteria: a case series including rare species. *Diagn Microbiol Infect Dis* 2008; 61:187-91. DOI: 10.1016/j.diagmicrobio.2008.01.004
8. Gaviña JM, García PJ, Garrido SM, Corey L, Boeckh M. Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. *Biol Blood Marrow Transplant*. 2000; 6(4):361-9. DOI: 10.1016/s1083-8791(00)70012-7

9. Kline S, Cameron S, Streifel A, Yakus MA, Kairis F, Peacock K et al. An outbreak of bacteremias associated with *Mycobacterium mucogenicum* in a hospital water supply. *Infect Control Hosp Epidemiol*. 2004; 25(12):1042-9. DOI: 10.1086/502341
10. Behra PRK, Pettersson BMF, Ramesh M, Dasgupta S, Kirsebom LA. Insight into the biology of *Mycobacterium mucogenicum* and *Mycobacterium neoaurum* clade members. *Sci Rep*. 2019; 9(1):19259. DOI: 10.1038/s41598-019-55464-5
11. Redelman-Sidi G, Sepkowitz KA. Rapidly growing mycobacteria infection in patients with cancer. *Clin Infect Dis*. 2010; 51(4):422-34. DOI: 10.1086/655140
12. Kodana M, Tarumoto N, Kawamura T, Saito T, Ohno H, Maesaki S et al. Utility of the MALDI-TOF MS method to identify nontuberculous mycobacteria. *J Infect Chemother*. 2016; 22(1):32-5. DOI: 10.1016/j.jiac.2015.09.006
13. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med*. 2007; 175(4):367-416. DOI: 10.1164/rccm.200604-571ST
14. Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. *Arthritis Rheumatol*. 2021; 73(8):1349-1365. DOI: 10.1002/art.41774